Clearant to Present at the Dutton Associates' ''Recognizing Opportunity'' Health Sciences Small Cap Conference; Clearant to Discuss New Sales and Marketing Strategy at the Event.LOS ANGELES Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850. -- Clearant, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CLRI CLRI Central Leather Research Institute (India) ) today announced that the Company will present at the Dutton Associates' "Recognizing Opportunity" Health Sciences Small Cap Conference to be held at the St. Regis Hotel in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden on May 31, 2006. Alain Delongchamp, chief executive officer of Clearant, will present on Wednesday, May 31, 2006 at 8:54 a.m. Pacific time (11:54 a.m. Eastern time) and will discuss the Company's new sales and marketing strategy, designed to sell Designed to Sell is an HGTV American reality television show hosted by Clive Pearse. The show focuses on the fixing up and renovation of a home that is about to go on the market. It is one half hour long and is produced by Pietown Productions. The show began airing in 2004. directly its sterile implants, using the CLEARANT PROCESS to surgeons, hospitals and clinics. Mr. Delongchamp also will present to small, informal groups of investment professionals during two breakout sessions in the afternoon. Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the "Investors" section on the Company's Web site at www.clearant.com. The presentation will be archived on the Web site and available for 30 days. For more conference information and registration, please visit www.jmdutton.com. About Clearant, Inc. Clearant, Inc. is a leader in pathogen inactivation inactivation /in·ac·ti·va·tion/ (in-ak?ti-va´shun) the destruction of biological activity, as of a virus, by the action of heat or other agent. for biological products. Clearant has developed the patent-protected CLEARANT PROCESS, which substantially reduces all types of pathogens in biological products while maintaining the functionality of the underlying protein. The Company plans to distribute directly to surgeons, hospitals and clinics CLEARANT PROCESS sterile implants starting mid 2006; in addition, Clearant continues to license the CLEARANT PROCESS and provides its patented sterilization sterilization Any surgical procedure intended to end fertility permanently (see contraception). Such operations remove or interrupt the anatomical pathways through which the cells involved in fertilization travel (see reproductive system). services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To-date more than 8,000 patients have been successfully implanted with a CLEARANT PROCESS sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the CLEARANT PROCESS reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the CLEARANT PROCESS can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion